GLIPR1 and cancer: To investigate the potential synergy of docetaxel and GLIPR1-ΔTM in inducing anti-cancer effects, we treated VCaP and PC-3 cells with various combinations of the two agents: 0.5, 1, 2, 5, 10, 20, 50, and 75nM docetaxel in both cell lines; 0, 10, 20, and 40 μg/ml GLIPR1-ΔTM in VCaP cells; and 0, 10, 20, 40, and 80 μg/ml GLIPR1-ΔTM in PC-3 cells.